EcoDrugPlus

Serum Amyloid P-Component-Like

Ensembl ID : ENSKMAG00000005846
Gene Symbol: LOC108241080
2 Cross references
406 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSKMAG00000013179
Gene Symbol: LOC108241946
2 Cross references
353 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSKMAG00000005874
Gene Symbol: LOC108241064
2 Cross references
406 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSKMAG00000015145
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSKMAG00000008393
Gene Symbol: SIRT1
3 Cross references
156 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSKMAG00000015172
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 3 Subunit Alpha-Like

Ensembl ID : ENSKMAG00000013339
Gene Symbol: LOC108229119
2 Cross references
249 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha B-Like

Ensembl ID : ENSKMAG00000019452
Gene Symbol: LOC108238657
3 Cross references
248 Possible Orthologues:

Sodium Channel Protein Type 8 Subunit Alpha-Like

Ensembl ID : ENSKMAG00000018319
Gene Symbol: LOC108235708
2 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSKMAG00000018380
Gene Symbol: SCN4A
4 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSKMAG00000006355
Gene Symbol: SCN8A
4 Cross references
215 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSKMAG00000013502
Gene Symbol: LOC108232048
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).